Journal: bioRxiv
Article Title: Peristromal niches protect lung cancers from targeted therapies through a combined effect of multiple molecular mediators
doi: 10.1101/2024.04.24.590626
Figure Lengend Snippet: A. Exogenous expression of HGF confers resistance to alectinib (25 mg/kg) in NSG xenografts. N=4 tumors for all groups except for HGF o/e control (N=2). Error bars represent SEM. B . Diagram of the experimental design to assess the impact of stromal activation of tumor cMET -mediated bypass signaling in vivo . C . Volumetric response dynamics of H3122 xenograft tumors in NSG and NSG hHGF hosts, continuously treated with 25 mg/kg alectinib or vehicle control. Error bars represent SEM; N= 4 & 18 for the control and alectinib-treated groups, respectively. D . Diagram of the experimental idea: cMET inhibition should suppress the enhanced relapse in NSG hHGF xenografts. E . Tumor response dynamics for vehicle control (N=4), 40 mg/kg capmatinib (N=4), 20 mg/kg alectinib (N=10) and alectinib/capmatinib (N=10) combination treated groups respectively. F . Representative images of anti-BrdU IHC from xenograft tumor tissues at the indicated time points. Arrows point to the examples of stromal regions defined by counterstain. P values in tumor growth analyses represents the significance of the interaction term of the repeated measurement 2-way ANOVA analyses between the indicated groups.
Article Snippet: The human HGF Antibody was purchased from R&D systems (AB-294-NA); murine HGF recombinant protein was purchased from Sino Biological (50038-MNAH-20).
Techniques: Expressing, Control, Activation Assay, In Vivo, Inhibition